We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

Back to rankings

1 hedge funds and large institutions have $34.3M invested in Ariad Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 191 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% less funds holding in top 10

Funds holding in top 10: 9 → 1 (-8)

98% less capital invested

Capital invested by funds: $2.13B → $34.3M (-$2.09B)

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 191

100% less funds holding

Funds holding: 200 → 1 (-199)

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.02%
Holding in Top 10
1
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-88.89%
% of All Funds
0.02%
New
1
Increased
–
Reduced
–
Closed
191
Calls
$31K
Puts
–
Net Calls
+$31K
Net Calls Change
+$16.5M

Top Buyers

Rank Fund Capital Flow
1
FPF
FNY Partners Fund
New York
+$32M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$225M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$218M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$182M
4
SCM
Sarissa Capital Management
Connecticut
-$160M
5
State Street
State Street
Massachusetts
-$97.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
26
Polar Capital
United Kingdom
– -$15.4M -1,235,000 Closed
Deutsche Bank
27
Deutsche Bank
Germany
– -$15.2M -1,225,891 Closed
Morgan Stanley
28
Morgan Stanley
New York
– -$13.4M -1,076,629 Closed
Bank of New York Mellon
29
Bank of New York Mellon
New York
– -$12.5M -1,005,186 Closed
OM
30
Opaleye Management
Massachusetts
– -$12.4M -1,000,000 Closed
HI
31
HBK Investments
Texas
– -$11.8M -947,249 Closed
MFP
32
Michael F. Price
– -$11.7M -940,000 Closed
RPAM
33
Rhenman & Partners Asset Management
Sweden
– -$11.1M -895,000 Closed
TA
34
Tamarack Advisers
California
– -$10.6M -850,000 Closed
Charles Schwab
35
Charles Schwab
California
– -$9.68M -778,437 Closed
Citigroup
36
Citigroup
New York
– -$9.68M -777,786 Closed
Renaissance Technologies
37
Renaissance Technologies
New York
– -$9.48M -762,481 Closed
GAI
38
General American Investors
New York
– -$8.88M -714,100 Closed
IBT
39
International Biotechnology Trust
United Kingdom
– -$8.18M -657,912 Closed
HS
40
HighVista Strategies
Massachusetts
– -$7.94M -638,086 Closed
CA
41
Commerzbank Aktiengesellschaft
Germany
– -$7.62M -612,886 Closed
Voloridge Investment Management
42
Voloridge Investment Management
Florida
– -$7.48M -601,463 Closed
Two Sigma Advisers
43
Two Sigma Advisers
New York
– -$7.08M -568,749 Closed
ECP
44
Elk Creek Partners
Colorado
– -$6.76M -543,063 Closed
TCIM
45
TIAA CREF Investment Management
New York
– -$6.34M -509,592 Closed
GPCM
46
Granite Point Capital Management
Massachusetts
– -$5.8M -466,015 Closed
PP
47
PDT Partners
New York
– -$5.21M -418,650 Closed
BG
48
Bellevue Group
Switzerland
– -$4.67M -375,000 Closed
UBS Group
49
UBS Group
Switzerland
– -$4.61M -370,402 Closed
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
– -$4.54M -364,838 Closed
1
2
3 4 5

ARIA Hedge Fund Activity: Q1 2017 in Review

1 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q1 2017, worth a combined $34.3M — down 98% from $2.13B a quarter earlier.

Sellers outnumbered buyers: 191 funds closed out of ARIA and 1 opened new positions — a net loss of 190 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was FNY Partners Fund, opening a new position worth an estimated $32M. The largest seller was Fidelity Investments, exiting entirely with an estimated $225M sold.

  • 1 institutional investor held Ariad Pharmaceuticals Inc (ARIA) as of Q1 2017, down from 200 in Q4 2016.
  • Funds reported $34.3M of Ariad Pharmaceuticals Inc stock for Q1 2017, down 98% quarter-over-quarter.
  • 1 fund opened new Ariad Pharmaceuticals Inc positions in Q1 2017 and 191 closed out, a net change of -190 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q1 2017 was FNY Partners Fund, an estimated $32M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q1 2017 was Fidelity Investments, an estimated $225M sold.

Based on aggregated 13F filings for Q1 2017.